Lipid metabolism in pancreatic cancer treatment

Figure 1 Schematic overview of lipid metabolism reprogramming and its therapeutic targeting in pancreatic cancer. This figure summarizes the key concepts of the manuscript, illustrating the six interconnected components: The four hallmark alterations in lipid metabolism, their multifaceted roles in inducing tumor progression and immunosuppression, and the emerging strategies for targeted therapy. FAO: Fatty acid oxidation; FASN: Fatty acid synthase; ACC: Acetyl-CoA carboxylase; LDLR: Low-density lipoprotein receptor; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; PC: Pancreatic cancer; DL-C: Low-density lipoprotein cholesterol; MDSCs: Myeloid-derived suppressor cells; STAT3: Signal transducer and activator of transcription 3; NF-κB: Nuclear factor kappa B; EGCG: Epigallocatechin gallate; HMGCR:3-hydroxy-3-methylglutaryl-CoA reductase; PPIs: Proton pump inhibitors; SCD: Stearoyl-CoA desaturase.